Literature DB >> 29955590

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.

Constantine E Kosmas1, Andreas Sourlas2, Kyriaki V Bouza3, Eddy DeJesus4, Delia Silverio5, Peter D Montan5, Eliscer Guzman6.   

Abstract

Entities:  

Year:  2018        PMID： 29955590      PMCID： PMC6015935          DOI： 10.21037/atm.2018.02.20

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

Review 1.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors:  James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

Review 2.  Statin use and the risk of developing diabetes: a network meta-analysis.

Authors:  Divyesh Thakker; Sunita Nair; Amit Pagada; Vinayak Jamdade; Anuradha Malik
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-06-09       Impact factor: 2.890

3.  Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.

Authors:  Michael J Koren; Marc S Sabatine; Robert P Giugliano; Gisle Langslet; Stephen D Wiviott; Helina Kassahun; Andrea Ruzza; Yuhui Ma; Ransi Somaratne; Frederick J Raal
Journal:  JAMA Cardiol       Date:  2017-06-01       Impact factor: 14.676

4.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

Review 5.  Proprotein convertase subtilisin/kexin type 9 inhibition.

Authors:  David A Marais; Dirk J Blom; Francine Petrides; Yann Gouëffic; Gilles Lambert
Journal:  Curr Opin Lipidol       Date:  2012-12       Impact factor: 4.776

6.  Statin therapy and risk of developing type 2 diabetes: a meta-analysis.

Authors:  Swapnil N Rajpathak; Dharam J Kumbhani; Jill Crandall; Nir Barzilai; Michael Alderman; Paul M Ridker
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 19.112

Review 7.  New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.

Authors:  Giuseppe Danilo Norata; Christie M Ballantyne; Alberico Luigi Catapano
Journal:  Eur Heart J       Date:  2013-03-18       Impact factor: 29.983

8.  Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

Authors:  Yue-Wei Qian; Robert J Schmidt; Youyan Zhang; Shaoyou Chu; Aimin Lin; He Wang; Xiliang Wang; Thomas P Beyer; William R Bensch; Weiming Li; Mariam E Ehsani; Deshun Lu; Robert J Konrad; Patrick I Eacho; David E Moller; Sotirios K Karathanasis; Guoqing Cao
Journal:  J Lipid Res       Date:  2007-04-20       Impact factor: 5.922

Review 9.  Sorting an LDL receptor with bound PCSK9 to intracellular degradation.

Authors:  Trond P Leren
Journal:  Atherosclerosis       Date:  2014-09-02       Impact factor: 5.162

10.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015.

Authors:  Gregory A Roth; Catherine Johnson; Amanuel Abajobir; Foad Abd-Allah; Semaw Ferede Abera; Gebre Abyu; Muktar Ahmed; Baran Aksut; Tahiya Alam; Khurshid Alam; François Alla; Nelson Alvis-Guzman; Stephen Amrock; Hossein Ansari; Johan Ärnlöv; Hamid Asayesh; Tesfay Mehari Atey; Leticia Avila-Burgos; Ashish Awasthi; Amitava Banerjee; Aleksandra Barac; Till Bärnighausen; Lars Barregard; Neeraj Bedi; Ezra Belay Ketema; Derrick Bennett; Gebremedhin Berhe; Zulfiqar Bhutta; Shimelash Bitew; Jonathan Carapetis; Juan Jesus Carrero; Deborah Carvalho Malta; Carlos Andres Castañeda-Orjuela; Jacqueline Castillo-Rivas; Ferrán Catalá-López; Jee-Young Choi; Hanne Christensen; Massimo Cirillo; Leslie Cooper; Michael Criqui; David Cundiff; Albertino Damasceno; Lalit Dandona; Rakhi Dandona; Kairat Davletov; Samath Dharmaratne; Prabhakaran Dorairaj; Manisha Dubey; Rebecca Ehrenkranz; Maysaa El Sayed Zaki; Emerito Jose A Faraon; Alireza Esteghamati; Talha Farid; Maryam Farvid; Valery Feigin; Eric L Ding; Gerry Fowkes; Tsegaye Gebrehiwot; Richard Gillum; Audra Gold; Philimon Gona; Rajeev Gupta; Tesfa Dejenie Habtewold; Nima Hafezi-Nejad; Tesfaye Hailu; Gessessew Bugssa Hailu; Graeme Hankey; Hamid Yimam Hassen; Kalkidan Hassen Abate; Rasmus Havmoeller; Simon I Hay; Masako Horino; Peter J Hotez; Kathryn Jacobsen; Spencer James; Mehdi Javanbakht; Panniyammakal Jeemon; Denny John; Jost Jonas; Yogeshwar Kalkonde; Chante Karimkhani; Amir Kasaeian; Yousef Khader; Abdur Khan; Young-Ho Khang; Sahil Khera; Abdullah T Khoja; Jagdish Khubchandani; Daniel Kim; Dhaval Kolte; Soewarta Kosen; Kristopher J Krohn; G Anil Kumar; Gene F Kwan; Dharmesh Kumar Lal; Anders Larsson; Shai Linn; Alan Lopez; Paulo A Lotufo; Hassan Magdy Abd El Razek; Reza Malekzadeh; Mohsen Mazidi; Toni Meier; Kidanu Gebremariam Meles; George Mensah; Atte Meretoja; Haftay Mezgebe; Ted Miller; Erkin Mirrakhimov; Shafiu Mohammed; Andrew E Moran; Kamarul Imran Musa; Jagat Narula; Bruce Neal; Frida Ngalesoni; Grant Nguyen; Carla Makhlouf Obermeyer; Mayowa Owolabi; George Patton; João Pedro; Dima Qato; Mostafa Qorbani; Kazem Rahimi; Rajesh Kumar Rai; Salman Rawaf; Antônio Ribeiro; Saeid Safiri; Joshua A Salomon; Itamar Santos; Milena Santric Milicevic; Benn Sartorius; Aletta Schutte; Sadaf Sepanlou; Masood Ali Shaikh; Min-Jeong Shin; Mehdi Shishehbor; Hirbo Shore; Diego Augusto Santos Silva; Eugene Sobngwi; Saverio Stranges; Soumya Swaminathan; Rafael Tabarés-Seisdedos; Niguse Tadele Atnafu; Fisaha Tesfay; J S Thakur; Amanda Thrift; Roman Topor-Madry; Thomas Truelsen; Stefanos Tyrovolas; Kingsley Nnanna Ukwaja; Olalekan Uthman; Tommi Vasankari; Vasiliy Vlassov; Stein Emil Vollset; Tolassa Wakayo; David Watkins; Robert Weintraub; Andrea Werdecker; Ronny Westerman; Charles Shey Wiysonge; Charles Wolfe; Abdulhalik Workicho; Gelin Xu; Yuichiro Yano; Paul Yip; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Theo Vos; Mohsen Naghavi; Christopher Murray
Journal:  J Am Coll Cardiol       Date:  2017-05-17       Impact factor: 24.094
View more
  3 in total

Review 1.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

Review 2.  Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

Authors:  Constantine E Kosmas; Delia Silverio; Andreas Sourlas; Frank Garcia; Peter D Montan; Eliscer Guzman
Journal:  Drugs Context       Date:  2018-11-28

Review 3.  Safety and Tolerability of PCSK9 Inhibitors: Current Insights.

Authors:  Constantine E Kosmas; Andreas Skavdis; Andreas Sourlas; Evangelia J Papakonstantinou; Edilberto Peña Genao; Rogers Echavarria Uceta; Eliscer Guzman
Journal:  Clin Pharmacol       Date:  2020-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.